Noble Financial analyst Robert LeBoyer reiterated a Buy rating on Genprex (GNPX – Research Report) today and set a price target of $5.00. The company’s shares closed yesterday at $2.09.
LeBoyer covers the Healthcare sector, focusing on stocks such as Ayala Pharmaceuticals, Tonix Pharma, and PDS Biotechnology. According to TipRanks, LeBoyer has an average return of 12.9% and a 37.31% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Genprex with a $5.00 average price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $3.62 and a one-year low of $1.17. Currently, Genprex has an average volume of 126.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Genprex, Inc. is a clinical stage gene therapy company, which engages in the development of novel proprietary technology platform for the treatment of cancer. It develops the Oncoprex immunogene therapy which targets the non-small cell lung cancer and other solid tumors. The company was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.
Read More on GNPX:
- SPAR Group, Inc. Reports Fiscal 2022 Second Quarter Results
- Legion Capital Recognized With Innovative Excellence Award 2022
- Beach Energy Limited (BEPTF) was downgraded to a Sell Rating at Macquarie
- Macquarie Sticks to Their Buy Rating for G.U.D. Holdings (GUDHF)
- BM Technologies Reports Record Second Quarter Results for Q2 2022
